Caprock Group LLC Sells 5,851 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Caprock Group LLC lessened its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,080 shares of the company’s stock after selling 5,851 shares during the quarter. Caprock Group LLC’s holdings in Elanco Animal Health were worth $839,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. increased its stake in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC bought a new stake in shares of Elanco Animal Health during the third quarter worth about $29,000. nVerses Capital LLC bought a new position in shares of Elanco Animal Health during the second quarter valued at $32,000. ORG Partners LLC acquired a new position in Elanco Animal Health during the 2nd quarter worth about $31,000. Finally, AM Squared Ltd acquired a new position in shares of Elanco Animal Health in the third quarter worth approximately $34,000. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ELAN. Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Trading Down 0.3 %

Shares of ELAN opened at $13.41 on Friday. The firm’s 50 day simple moving average is $13.72 and its 200 day simple moving average is $14.75. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market capitalization of $6.63 billion, a P/E ratio of 33.51, a P/E/G ratio of 1.39 and a beta of 1.41. Elanco Animal Health Incorporated has a 1-year low of $11.40 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the business posted $0.18 earnings per share. The company’s revenue was down 3.6% on a year-over-year basis. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.